Health economic modeling

Relevant publications

1. O. Alagoz, B. Arrick, C. Speers, M. Ward, T. King, J. Bennett, A. B. Ozbay, and Q. Le (2023). "EE269 Cost-Effectiveness of Profile Omission of Local Adjuvant Radiotherapy (POLAR), A Novel Genomic Signature, after Breast Conserving Surgery for Women with Invasive Early-Stage Breast Cancer (ESBC)." Value in Health 26(6): S108. Poster presentation at ISPOR Annual Conference, May 7-10, 2023, Boston, Massachusetts. 

2. J.M. Yeh, K.P. Lowry, C.B. Schechter, L.R. Diller, G. O’Brien, O. Alagoz, et al. (2022), “Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness,” Journal of the National Cancer Institute, 114(2):235–244.

3. B. Niu, N. Mukhtarova, O. Alagoz, K. Hoppe (2022), “Cost-effectiveness of Telehealth with Remote Patient Monitoring for Postpartum Hypertension,” Journal of Maternal-Fetal & Neonatal Medicine, 35(25):7555-7561.

4. J.M. Yeh, K.P. Lowry, C.B. Schechter, L.R. Diller, O. Alagoz, G.T. Armstrong, J.M. Hampton, W. Leisenring, Q. Liu, J.S. Mandelblatt, D.L. Miglioretti, C.S. Moskowitz, K.C. Oeffinger, A. Trentham-Dietz, N.K. Stout (2020), “Clinical benefits, harms and cost-effectiveness of breast cancer screening for survivors of childhood cancer treated with chest radiation: A comparative modeling study,” Annals of Internal Medicine, 173(5):331-341.

5. A.K. Barker*, E. Scaria*, N. Safdar, O. Alagoz (2020), “Evaluation of the Cost-effectiveness of Infection Control Strategies to Reduce Hospital-Onset Clostridioides difficile Infection,” JAMA Network Open, 3(8):e2012522.

6. A. Hajjar*, M.A. Ergun*, O. Alagoz, M. Rampurwala (2019), “Cost-Effectiveness of Adjuvant Paclitaxel and Trastuzumab for Early-Stage Node-Negative, HER2-Positive Breast Cancer,” PLoS ONE, 14(6):e0217778.

7. N. Mittmann, N.K. Stout, A.T.A. Tosteson, A. Trentham-Dietz, O. Alagoz, M.J. Yaffe (2018), “Cost-effectiveness of Mammography Policies from a Publicly-funded Health Systems Perspective,” CMAJ Open, 6(1):E77-E86.

8. V. Ozmen, S. Gurdal, N. Cabioglu, B. Ozcinar, N. Ozaydin, A. Kayhan, E. Aribal, C. Sahin: Saip, O. Alagoz (2017), “Potential Cost-Effectiveness of Breast Cancer Screening in Turkey: Results from Bahcesehir Mammography Screening Project,” European Journal of Breast Health, 13(3):117-122

9. F.S. Erenay*, O. Alagoz, R. Banerjee, A. Said, R.R. Cima (2016), “Cost-effectiveness of Alternative Colonoscopy Surveillance Strategies after Initial Treatment to Mitigate the Risk of Metachronous Colorectal Cancer,” Cancer, 122:2560-2570.

10. O. Alagoz, D. Durham, K. Kasirajan (2016), “Cost Effectiveness of One-time Genetic Testing to Minimize Lifetime Adverse Drug Reactions,” The Pharmacogenomics Journal, 16(2), 129-136.

11. N. Mittmann, N.K. Stout: Lee, A.T.A. Tosteson, A. Trentham-Dietz, O. Alagoz, M.J. Yaffe (2015), “Total cost-effectiveness of different breast screening scenarios,” Health Reports, 26(12):16-25.

12. C.I. Lee, M. Cevik*, O. Alagoz, B.L. Sprague, A.N.A. Tosteson, D.L. Miglioretti, K. Kerlikowske, N.K. Stout, J.G. Jarvik, S.D. Ramsey, C.D. Lehman, (2015) “Cost-Effectiveness of Adjunct Digital Breast Tomosynthesis for Screening Women with Dense Breasts,” Radiology, 274(3):772-780.

13. B.L. Sprague, N.K. Stout, C. Schechter, N.T. van Ravesteyn, M. Cevik*, O. Alagoz, C.I. Lee, J.J. van den Broek, D.L. Miglioretti, J.S. Mandelblatt, H.J. de Koning, K. Kerlikowske, C.D. Lehman, A.N. A. Tosteson (2015), “Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts,” Annals of Internal Medicine, 162(3), 157-166.

14. N.K. Stout, S.J. Lee, C.B. Schechter, K. Kerlikowske, O. Alagoz, D. Berry, D.S.M. Buist, M. Cevik*, G. Chicholm, H.J. de Koning, H. Huang,  R.A. Hubbard, D.L. Miglioretti, M.F. Munsell, A. Trentham-Dietz, N.T. van Ravesteyn, A.N.A. Tosteson, J.S. Mandelblatt (2014), “Benefits, harms, and costs for breast cancer screening in the US following implementation of digital mammography,” Journal of the National Cancer Institute, 106(6): dju092.

15. M. Ayvaci*, J. Shi*, O. Alagoz, and S. Lubner (2012), "Cost-Effectiveness of Adjuvant FOLFOX and 5FU2/LV Chemotherapy for Patients with Stage II Colon Cancer," Medical Decision Making, 33(4):521-532.